Health Care Insurer Mergers: Who Got the Best Deal?

You’ve heard the prices, now here are the multiples. After hours of teasing about a definitive agreement, Anthem, Inc. (NYSE: ANTM) finally reached an agreement to acquire Cigna Corp. (NYSE: CI) for $54.2 billion. That works out to 1.5x price/revenue and 13.9x price/EBITDA. The deal followed Aetna’s (NYSE: AET) $37 billion acquisition of Humana Inc. (NYSE: HUM), which gives us a multiple […]

Physician Medical Group M&A Is Going Strong

Nearly seven full months through the year, M&A in the Physician Medical Group (PMG) sector is on pace to post its second-highest deal volume since 2000. As of July 24, we’ve recorded 47 acquisitions, which is second only to 2011, when 56 transactions were announced in the same time period. The biggest deal in the […]

Almost Family Buys into In-Home Assessments

Almost Family, Inc. (NASDAQ: AFAM) made a strategic acquisition last week that moves it into the growing health assessment market. The company paid $13,354,200 ($2 million in cash and approximately 260,000 shares of AFAM common stock) to buy Ingenios Health Co. of Jacksonville, Florida. Ingenios provides technology-enabled in-home clinical assessments for Medicare Advantage, Managed Medicaid and Commercial Exchange […]

Indian Drug Maker Gains a Manufacturing Toehold in the U.S.

Mumbai-based Lupin Limited (NSE: LUPIN.NS) produces a wide range of branded and generic formulations and APIs globally. Last week it paid $880 million for bought GAVIS Pharmaceuticals LLC and a subsidiary, Novel Laboratories. The acquisition enhances Lupin’s scale in the U.S. generic market and broadens its pipeline in dermatology, controlled substance products and other high-value and niche generics. Gavis had […]

Celgene Continues Its Buying Spree

Celgene Corporation (NASDAQ: CELG) made yet another major acquisition last week, picking up Receptos, Inc. (NASDAQ: RCPT) for $7.2 billion. The acquisition significantly boosts Celgene’s Inflammation and Immunology portfolio with the addition of Receptos’ lead product candidate, Ozanimod, which is in Phase 3 tests to treat immune-inflammatory indications in irritable bowel syndrome and relapsing multiple […]

Q2:15 Hospital M&A Stayed Active

Hospital mergers and acquisitions didn’t flag in the second quarter of 2015, with at least 23 “definitive agreements” signed. That’s equal to the 23 recorded in the first quarter of the year. (We wait until hospital transactions get that far in the process, because so many fall apart after they sign a letter of intent.) […]

Molina Healthcare Steps Up Its Game

The big buzz in the Managed Care sector is the $37 billion bid from Aetna (NYSE: AET) for Humana Inc. (NYSE: HUM), of course. While that deal is lauded for the Medicare assets it brings to Aetna, Molina Healthcare (NYSE: MOH) continues to beef up on Medicaid assets. Last week it announced two deals, one […]